文献速递神经免疫

复发无关进展与复发相关恶化对复发型多发性硬化确认残疾累积的贡献

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
PubMed 文献 · JAMA Neurol · 2020-01-01

该研究汇总OPERA I和II两项随机对照试验数据,分析复发型多发性硬化患者中复发相关恶化(RAW)与复发无关进展(PIRA)对确认残疾累积(CDA)的贡献。结果显示PIRA是CDA的主要驱动因素,奥瑞利珠单抗较干扰素β-1a降低CDA、PIRA和RAW风险。

要点

  • 复发型多发性硬化中多数残疾累积为复发无关进展(PIRA)。
  • 奥瑞利珠单抗较干扰素β-1a降低确认残疾累积风险(HR 0.67)。
  • 奥瑞利珠单抗降低PIRA(HR 0.78)和RAW(HR 0.47)风险。

核心结论

  • 复发型多发性硬化中大多数残疾累积与明显复发无关,提示存在潜在进展。
  • 奥瑞利珠单抗在预防RAW和PIRA方面均优于干扰素β-1a。

研究设计与样本

  • 汇总OPERA I和II两项相同III期多中心双盲双模拟平行组随机对照试验的意向治疗人群数据。
  • 共纳入1656例复发型多发性硬化患者,随机接受奥瑞利珠单抗600mg每24周静脉输注或干扰素β-1a 44μg皮下注射每周三次,治疗96周。

主要发现

  • 96周时,12周复合CDA在干扰素β-1a组发生223例(Kaplan-Meier估计29.6%),奥瑞利珠单抗组167例(21.1%)。
  • 24周复合CDA在干扰素β-1a组发生170例(22.7%),奥瑞利珠单抗组129例(16.2%)。
  • PIRA是12周和24周复合CDA的主要贡献因素:干扰素β-1a组分别为174/223(78.0%)和137/170(80.6%),奥瑞利珠单抗组分别为147/167(88.0%)和115/129(89.1%)。
  • 少数CDA由RAW事件解释:12周复合CDA中69/390(17.7%),24周复合CDA中52/299(17.4%)。
  • 奥瑞利珠单抗较干扰素β-1a降低复合CDA风险(HR 0.67)、确认PIRA风险(HR 0.78)和RAW风险(HR 0.47)。

关键数值与推荐

  • 确认残疾累积定义为3项指标(EDSS、定时25英尺步行、9孔钉柱测试)中至少1项增加,经3或6个月确认。
  • CDA按与确认临床复发的时间关联分类为PIRA或RAW。

临床怎么用

  • 临床评估复发型多发性硬化残疾进展时需关注独立于复发的进展(PIRA)。
  • 奥瑞利珠单抗可同时降低复发相关恶化和复发无关进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and secondary progressive multiple sclerosis. OBJECTIVE: To investigate the contributions of relapse-associated worsening vs relapse-independent progression to overall confirmed disability accumulation (CDA) and assess respective baseline prognostic factors and outcomes of 2 treatments. DESIGN, SETTING, AND PARTICIPANTS: Analyses occurred from July 2015 to February 2020 on pooled data from the intention-to-treat population of 2 identical, phase 3, multicenter, double-blind, double-dummy, parallel-group randomized clinical trials (OPERA I and II) conducted between August 2011 and April 2015. In the trials, patients with relapsing multiple sclerosis (RMS), diagnosed using the 2010 revised McDonald criteria, were randomized from 307 trial sites in 56 countries; resulting data were analyzed in the pooled data set. INTERVENTIONS: Participants were randomized 1:1 to receive 600 mg of ocrelizumab by intravenous infusion every 24 weeks or subcutaneous interferon β-1a 3 times a week at a dose of 44 μg throughout a 96-week treatment period. MAIN OUTCOMES AND MEASURES: Confirmed disability accumulation was defined by an increase in 1 or more of 3 measures (Expanded Disability Status Scale, timed 25-ft walk, or 9-hole peg test), confirmed after 3 or 6 months, and classified per temporal association with confirmed clinical relapses (PIRA or RAW). RESULTS: In the pooled OPERA I and II population (1656 of 2096 eligible participants), baseline demographics and disease characteristics were similar for patients randomized to interferon β-1a vs ocrelizumab (mean [SD] age, 37.2 [9.2] vs 37.1 [9.2] years; 552 [66.6%] vs 541 women [65.4%]). After 96 weeks, 12-week composite CDA had occurred in 223 (29.6% by Kaplan-Meier estimate) randomized to interferon β-1a and 167 (21.1%) randomized to ocrelizumab; 24-week composite CDA had occurred in 170 (22.7%) taking interferon β-1a and 129 (16.2%) taking ocrelizumab. The PIRA events were the main contributors to 12-week and 24-week composite CDA after 96 weeks in patients treated with interferon β-1a (174 of 223 [78.0%] and 137 of 170 [80.6%], respectively) and ocrelizumab (147 of 167 [88.0%] and 115 of 129 [89.1%], respectively); a minority had CDA explained by RAW events (69 of 390 [17.7%] and 52 of 299 [17.4%], respectively). Very few patients with composite CDA experienced both RAW and PIRA events (17 of 390 [4.4%] for 12-week and 15 of 299 [5.0%] for 24-week composite CDA). Ocrelizumab (vs interferon β-1a) was associated with reduced risk of composite CDA (hazard ratio [HR], 0.67) and confirmed PIRA (HR, 0.78) and RAW (HR, 0.47) events. CONCLUSIONS AND RELEVANCE: Most disability accumulation in RMS is not associated with overt relapses. This indicates an underlying progression in this typical RMS population and challenges the current clinical distinction of relapsing and progressive forms of multiple sclerosis. Ocrelizumab was superior to interferon β-1a in preventing both RAW and PIRA. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: OPERA I (NCT01247324) and OPERA II (NCT01412333).

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020. PMID: 32511687. doi:10.1001/jamaneurol.2020.1568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。